A recent article published on PharmaTimes looks at what the future may hold for real-world evidence amid rising interest in the pharmaceutical industry.
The author, Verantos CEO Dan Riskin, widespread efforts to establish robust RWE “provides a significant opportunity to refine the standard of care.”
“Moving from generalised RCTs to tailored therapy enabled by added RWE represents a sea change in healthcare,” Riskin writes. “There is no other way to form precise care with sub-groups who were not analysed or included in the original clinical trials due to strict inclusion and exclusion criteria.”
To read the full article, click here.